New hope for Hard-to-Treat cancers: drug targets KRAS G12D mutation
NCT ID NCT05533463
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HRS-4642 in 102 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must have tried other treatments and have at least one measurable tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4642 (a drug that targets the KRAS G12D mutation)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have a specific KRAS G12D mutation.
What could go wrong
This is a very early Phase 1 trial, so the drug may not prove safe or effective. Only 102 participants are enrolled, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China